Benign Prostatic Hyperplasia – Prostate Cancer – Prostatitis

Medrogestone

No Comments

Drug Approvals

(British Approved Name, US Adopted Name, rINN)

INNs in other languages (French, Latin, and Spanish):

Synonyms: AY-62022; Medrogeston; Medrogestona; Medrogestoni; Medrogestonum; Metrogestone; NSC-123018; R-13-615
BAN: Medrogestone
USAN: Medrogestone
INN: Medrogestone [rINN (en)]
INN: Medrogestona [rINN (es)]
INN: Médrogestone [rINN (fr)]
INN: Medrogestonum [rINN (la)]
INN: Медрогестон [rINN (ru)]
Chemical name: 6,17α-Dimethylpregna-4,6-diene-3,20-dione
Molecular formula: C23H32O2 =340.5
CAS: 977-79-7
ATC code: G03DB03

Profile

Medrogestone is a progestogen structurally related to progesterone that is used in the treatment of menstrual disorders, and as the progestogen in menopausal HRT. It is usually given orally in daily doses of 5 to 10 mg, generally in a cyclical regimen. Higher doses were used in the treatment of endometrial carcinoma, prostatic hyperplasia, and breast disorders including carcinoma. It has also been used for threatened or recurrent miscarriage, but such use is not recommended unless there is proven progesterone deficiency.

Preparations

Proprietary Preparations

Austria: Colpron

Belgium: Colpro †

France: Colprone

Germany: Prothil

Hong Kong: Colprone †

Italy: Colprone †

South Africa: Colpro †

Spain: Colpro

Switzerland: Colpro

Multi-ingredient

Austria: Premarin compositum † Premarin Plus

Belgium: Premplus

Czech Republic: Presomen Compositum †

Germany: Presomen Compositum

Hong Kong: Prempak

Italy: Prempak †

Malaysia: Prempak

The Netherlands: Premarin Plus

Portugal: Premarin Plus

South Africa: Prempak

Switzerland: Premarin Plus

 
Tags:
Posted in: Drugs

Leave a Reply

You must be logged in to post a comment.